# FIRST LIGHT

06 February 2026

## RESEARCH

**GREENPLY INDUSTRIES | TARGET: Rs 280 | +27% | BUY**

Volume-led growth intact; capacity expansion on cards

**LIC | TARGET: Rs 1,058 | +26% | BUY**

Continued VNB margin expansion

**ASTRAL | TARGET: Rs 1,610 | +7% | HOLD**

Volume strength offsets pricing and cost headwinds

**CENTURY PLYBOARDS | TARGET: Rs 840 | +7% | HOLD**

Volume-led growth continues; incremental capex planned

**ALEMBIC PHARMA | TARGET: Rs 1,013 | +25% | BUY**

Domestic business expected to recover from FY27

**CERA SANITARYWARE | TARGET: Rs 6,100 | +21% | BUY**

Q3FY26: Topline rebound, margins under pressure

---

## SUMMARY

### GREENPLY INDUSTRIES

- Topline beat by ~6%, while EBITDA and APAT miss by ~8% and ~26% in Q3FY26
- Plywood/ MDF revenue grew 9%/12% YoY, led by volume growth of 13%/15% YoY. Realisations decline ~5%/2% YoY
- Revise estimates, roll forward to Dec-26TP of Rs 280; upgrade to BUY

**Click here for the full report.**

**BOBCAPS Research**
research@bobcaps.in

## LIC

- VNB margin continued to expand 186bps YoY in 3Q, leading to strong absolute VNB growth
- Overall strong APE growth, with individual and group APE increasing by 12% YoY and 23% YoY in 9MFY26
- Maintain BUY on LICI with TP of Rs 1,058 (earlier Rs 1,120), assigning a multiple of 0.7x its Dec'27 E P/EV

**Click here for the full report.**

## ASTRAL

- Broadly in-line performance, revenue /EBITDA/ Adj PAT was 2% above our estimates.
- Revenue grew 10% YoY led by 8% / 18% YoY growth in the sales of plumbing /paints and adhesives respectively
- Revise estimates, roll forward to Dec-27EPS, ascribe unchanged 1YF multiple of 55x to arrive at a TP of 1,610; Maintain HOLD

**Click here for the full report.**

## CENTURY PLYBOARDS

- Beats revenue estimates, miss on margins. Revenue grew a robust 18% YoY, led by Plywood (+15% YoY), MDF (+19% YoY) and PB (+84% YoY)
- Volume growth was well supported by improving realisations across segments, excluding PB where realisations declined (-15% YoY)
- Revise estimates, roll forward to Dec-27EPS, ascribe unchanged 1YF multiple of 40x and arrive at TP of Rs 840. Maintain HOLD

**Click here for the full report.**

## ALEMBIC PHARMA

- Sales/EBITDA/PAT were 0.5%/-5.8%/-24.6% below our estimates due to 5% higher RM cost. APAT was 1.2% below our estimates
- Domestic sales to pick from 1QFY27 and growth likely to report at par with the IPM with the aid of internal restructuring
- Lower EBITDA margin led to reduction in EPS by 17%/10%6% for FY26/27E/&28E. Reduce ascribed PE to 21 to arrive at a PT of Rs 1013

**Click here for the full report.**

## CERA SANITARYWARE

- Revenue beats estimates by ~7%, while cost inflation led to EBITDA and APAT miss by ~18% and ~25% in Q3FY26
- Revenue grew 10% YoY, led by 18%/6% YoY growth in Faucets/Sanitaryware, respectively
- Revise estimates downwards, roll forward to Dec-26 TP of Rs 6,100 (ascribe 30x Dec-27EPS), maintain BUY

**Click here for the full report.**

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

**BUY**
**TP: Rs 280 | 27%**

**GREENPLY INDUSTRIES** | Building Materials | 06 February 2026

# Volume-led growth intact; capacity expansion on cards

- **Topline beat by ~6%, while EBITDA and APAT miss by ~8% and ~26% in Q3FY26**
- **Plywood/ MDF revenue grew 9%/12% YoY, led by volume growth of 13%/15% YoY. Realisations decline ~5%/2% YoY**
- **Revise estimates, roll forward to Dec-26TP of Rs 280; upgrade to BUY**

Vineet Shanker
Research Analyst
research@bobcaps.in

**Mixed Q3:** MTLM reported a moderate revenue beat of 6% in Q3FY26, with operating income at Rs 6.7 bn (+9.6% YoY), driven by healthy volume growth across plywood and MDF, partly offset by lower realisations. However, EBITDA was at Rs 589mn (-8% vs our estimate), as higher employee and other costs offset operating leverage. Consequently, APAT declined 31% YoY to Rs 170mn, missing our estimate by 25.7%, impacted by elevated interest costs and adverse non-operating items.

**Highlights:** Plywood revenues grew 9% YoY, led by strong volumes (+12.6% YoY) despite a 5.1% YoY decline in realisations, due to mix pressure. MDF revenues increased 11.7% YoY, supported by healthy volumes (+14.5% YoY), though pricing remained soft (-2.4% YoY). Consolidated EBITDA margin contracted marginally by 5 bps YoY to 8.7%. Net debt went up to Rs 5.3 bn (vs Rs 5.1 bn in Sep'25).

**Guidance:** Management reiterated double-digit volume growth in FY26 across plywood and MDF segments. Plywood is expected to deliver mid-teens volume growth, driven by deeper distribution and continued traction in the mid-segment. MDF is expected to see a sharp rebound from Q4FY26, with >20% YoY sales growth in Q4FY26 and EBITDA margins recovering toward ~16%, supported by normalised operations and higher utilisation. Capex across MDF, plywood, PVC and WPC will be largely funded through internal accruals, with debt-to-equity targeted at 0.5–0.6x by FY26-end.

**Revise estimates, upgrade to BUY from HOLD:** We upgrade MTLM to BUY from HOLD, as the moderation in near-term earnings seems largely priced in, while medium-term earnings growth remains attractive with an EPS CAGR of 20% over FY25-FY28E. The stock trades at 20x 1YF P/E vs 5Y average of 30x, offering a favourable risk-reward. We revise our FY26-28E estimates to factor in the capacity addition and rise in finance cost; as capacity expansion to be largely funded by borrowings. We roll forward our valuation to Dec-27EPS, valuing 22x (vs 25x earlier, revising our multiple to reflect the rising debt-to-equity ratio) and arrive at TP of Rs 280.

## Key changes

| Target | Rating |
|---|---|
| ▼ | ▲ |

| | |
|---|---|
| Ticker/Price | MTLM IN/Rs 220 |
| Market cap | US$ 304.3mn |
| Free float | 48% |
| 3M ADV | US$ 0.5mn |
| 52wk high/low | Rs 352/Rs 215 |
| Promoter/FPI/DII | 52%/4%/32% |

Source: NSE | Price as of 5 Feb 2026

## Key financials

| Y/E 31 Mar | FY25A | FY26E | FY27E |
|---|---|---|---|
| Total revenue (Rs mn) | 24,876 | 26,366 | 28,390 |
| EBITDA (Rs mn) | 2,377 | 2,560 | 3,318 |
| Adj. net profit (Rs mn) | 916 | 913 | 1,405 |
| Adj. EPS (Rs) | 7.3 | 7.3 | 11.2 |
| Consensus EPS (Rs) | 7.3 | 9.4 | 14.7 |
| Adj. ROAE (%) | 12.1 | 10.7 | 14.6 |
| Adj. P/E (x) | 30.0 | 30.1 | 19.6 |
| EV/EBITDA (x) | 13.6 | 12.7 | 10.3 |
| Adj. EPS growth (%) | 19.9 | (0.3) | 53.8 |

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance




Source: NSE

**BUY**
**TP: Rs 1,058 | ⮝ 26%**

LIC | Insurance | 06 February 2026

## Continued VNB margin expansion

- **VNB margin continued to expand 186bps YoY in 3Q, leading to strong absolute VNB growth**
- **Overall strong APE growth, with individual and group APE increasing by 12% YoY and 23% YoY in 9MFY26**
- **Maintain BUY on LICI with TP of Rs 1,058 (earlier Rs 1,120), assigning a multiple of 0.7x its Dec'27 E P/EV**

Vijiya Rao
Research Analyst
Niraj Jalan
Research Analyst
research@bobcaps.in

**Performance above expectations:** LICI reported better-than-expected operating performance, with APE, VNB and VNB margin higher by 17%, 34% and 271bps respectively in Q3FY26 — above our estimates, albeit on a lower base of Q3FY25.

**Continued VNB margin expansion:** VNB margins witnessed a sharp expansion of 186bps YoY to 21.22% in Q3FY26 (vs 19.36% in Q3FY25 vs 19.33% in Q2FY26), primarily driven by a favourable product mix. Share of non-par products rose to 25.5% vs. 20.5% in Q3FY25 (on APE basis) with a 48% impact to the VNB margins and favorable yield curve movement also aided the VNB margin. ULIPs share too increased to 9.8%% vs. 8.1% in Q3FY25. There was an unfavourable impact of 2.8%, on account of GST, persistency, and alignment of expenses in the Group segment to the VNB margins during the quarter. Par share declined to 43.9% vs. 44.4% in Q3FY25. VNB came in at Rs 31.8 bn, up 65% YoY (up 28% YoY in 9MFY26). The company's strategic shift towards a higher non-participating product mix is progressing well, with plans to further strengthen it through new product launches in the non-par segment.

**APE growth:** APE grew 51% YoY in Q3FY26 (16% YoY in 9MFY26), on lower base of Q3FY25. Overall industry APE grew 13% YoY in 9MFY26 with players clocking a growth of 13% YoY in 9MFY26. Individual APE and group APE witnessed 61% YoY (12% YoY in 9MFY26) and 31% YoY (23% YoY in 9MFY26) in Q3FY26. The company reiterated its focus on sustainable profit growth, new business performance, and top line growth.

**We maintain BUY on LICI:** LICI reported a better-than-expected APE, VNB and VNB with robust growth (on a lower base), owing to the high-margin non-par share further moving up (favourable product mix). With continued focus on the expanding non-par share in the product mix, management foresees margin expansion and balancing the APE and absolute VNB growth. We largely maintain estimates with VNB margins to be in the 18-19% range in FY26-FY28E. Hence, we maintain BUY on LICI with TP to Rs 1,058, (previously Rs 1,120) assigning a multiple of 0.7x its Dec'27E P/EV.

### Key changes

| Target | Rating |
|---|---|
| ▼ | ◀ ▶ |

| | |
|---|---|
| Ticker/Price | LICI IN/Rs 840 |
| Market cap | US$ 58.8bn |
| Free float | 0% |
| 3M ADV | US$ 11.9mn |
| 52wk high/low | Rs 980/Rs 715 |
| Promoter/FPI/DII | 97%/0%/1% |

Source: NSE | Price as of 5 Feb 2026

### Key financials

| Y/E 31 Mar | FY25A | FY26E | FY27E |
|---|---|---|---|
| NBP (Rs mn) | 22,67,855 | 24,81,397 | 26,79,909 |
| APE (Rs mn) | 5,68,270 | 6,45,935 | 7,48,550 |
| VNB (Rs mn) | 1,00,110 | 1,19,498 | 1,41,476 |
| Embedded Value (Rs | 77,68,750 | 86,07,315 | 95,29,047 |
| VNB margin (%) | 17.6 | 18.5 | 18.9 |
| EVPS (Rs) | 1,228.3 | 1,360.8 | 1,506.6 |
| EPS (Rs) | 76.1 | 94.6 | 105.8 |
| Consensus EPS (Rs) | 76.1 | 83.3 | 91.3 |
| P/EV (x) | 0.7 | 0.6 | 0.6 |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance




Source: NSE

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

**HOLD**
**TP: Rs 1,610 | ⮝ 7%**

**ASTRAL** | Building Materials | 06 February 2026

## Volume strength offsets pricing and cost headwinds

- **Broadly in-line performance, revenue /EBITDA/ Adj PAT was 2% above our estimates.**
- **Revenue grew 10% YoY led by 8% / 18% YoY growth in the sales of plumbing /paints and adhesives respectively**
- **Revise estimates, roll forward to Dec-27EPS, ascribe unchanged 1YF multiple of 55x to arrive at a TP of 1,610; Maintain HOLD**

Vineet Shanker
Research Analyst
research@bobcaps.in

**Beats estimates, volume growth surprises; Paints & Adhesives report strong growth (+18% YoY):** ASTRA beats our estimates for Q3FY26 (Revenue: +2%; EBITDA: +2%; PAT: +2%), due to the strong pipe sales volume (up 17% YoY vs our estimate of 12% YoY growth). ASTRA revenue/EBITDA/APAT grew by 10%/8%/4% YoY in Q3FY26.

**Pricing pressure led to margin contraction (-30bps YoY):** Pipes business continued to deliver strong volume-led growth, with pipes volumes up 17% YoY in Q3FY26. However, realisations declined 8% YoY, due to pricing corrections, leading to a modest contraction in segment EBITDA margins (–59 bps YoY to 17.0%). Pains & adhesives segment maintained healthy growth, with revenue up 15% YoY while operating loss widened to Rs 30mn vs Rs 20mn in Q3FY25. Overall, ASTRA's performance in Q3FY26 reflected resilient demand and market share gains (outperformed peers – SI volume growth +16% YoY, Apollo volume declined 6% YoY, while Finolex volume declined 14% YoY) offset by pricing pressure (Inventory loss reported during Q3 was Rs 220mn) and cost normalisation across segments.

**Maintains guidance as PVC resin prices stabilise:** Management maintained its guidance for mid-teens volume growth in pipes. This was driven by market-share gains, improving PVC resin pricing scenario leading to restocking by the channel and ramp-up at newer plants. Pipe margins are expected to improve sequentially, as polymer price volatility eases and inventory losses reverse. Pains and adhesives remain on a medium-term scale-up path, with profitability improving gradually as operations stabilise.

**Tweak estimates, maintain HOLD:** We expect ASTRA EPS to grow at a strong 20% CAGR with a healthy ROE of 17% over FY25-FY28E. However, we believe the stock is richly valued (trading at 61x on 1YF P/E vs 5Y pre-Covid average of 45.0x). We have tweaked our FY25-28E estimates marginally and ascribe unchanged 1YF multiple of 55x to arrive at TP of Rs 1,610 per share. We maintain HOLD, on a limited upside.

### Key changes

| Target | Rating |
|---|---|
| ▼ | ◀ ▶ |

| | |
|---|---|
| Ticker/Price | ASTRA IN/Rs 1,504 |
| Market cap | US$ 4.5bn |
| Free float | 46% |
| 3M ADV | US$ 10.5mn |
| 52wk high/low | Rs 1,594/Rs 1,232 |
| Promoter/FPI/DII | 54%/17%/17% |

Source: NSE | Price as of 5 Feb 2026

### Key financials

| Y/E 31 Mar | FY25A | FY26E | FY27E |
|---|---|---|---|
| Total revenue (Rs mn) | 58,324 | 64,036 | 74,993 |
| EBITDA (Rs mn) | 9,459 | 10,048 | 12,175 |
| Adj. net profit (Rs mn) | 5,238 | 5,425 | 6,781 |
| Adj. EPS (Rs) | 19.5 | 20.2 | 25.2 |
| Consensus EPS (Rs) | 19.5 | 21.3 | 27.3 |
| Adj. ROAE (%) | 15.0 | 13.9 | 15.5 |
| Adj. P/E (x) | 77.2 | 74.6 | 59.6 |
| EV/EBITDA (x) | 42.2 | 39.7 | 32.6 |
| Adj. EPS growth (%) | (4.9) | 3.6 | 25.0 |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance




Source: NSE

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

**HOLD**
**TP: Rs 840 | ⮝ 7%**

**CENTURY PLYBOARDS** | Building Materials | 06 February 2026

# Volume-led growth continues; incremental capex planned

- **Beats revenue estimates, miss on margins. Revenue grew a robust 18% YoY, led by Plywood (+15% YoY), MDF (+19% YoY) and PB (+84% YoY)**
- **Volume growth was well supported by improving realisations across segments, excluding PB where realisations declined (-15% YoY)**
- **Revise estimates, roll forward to Dec-27EPS, ascribe unchanged 1YF multiple of 40x and arrive at TP of Rs 840. Maintain HOLD**

Vineet Shanker
Research Analyst
research@bobcaps.in

**Beats topline (7% above our est.), slight miss on margin (-40bps below estimates):** CPBI beats our estimate for Q3FY26 (Revenue: +7%; EBITDA: +4%) driven by strong performance of the plywood & MDF segments. Overall, CPBI revenue/EBITDA/APAT grew by 18%/32%/16% YoY during the quarter, supported by healthy volume growth; though higher depreciation and interest expenses capped earnings upside; adjusted PAT grew 16% YoY.

**Robust volume growth:** CPBI delivered a strong volume growth for its plywood (+17% YoY) and MDF (+13%) segments in Q3FY26, due to its focus on dealer expansion. While PB reported a robust 2x volume growth, Laminate segment volume performance declined (-7% YoY). Particleboard segment delivered the highest-ever quarterly revenue of Rs 650mn, supported by higher volumes and improving capacity utilisation. MDF reported margin contraction on account of product mix and cost pressures. Laminates reported a sharp improvement in margin, due to premiumisation drive.

**Broadly maintains guidance, optimistic for FY27; capex on cards for FY28-29:** Management guided for double-digit volume growth across the plywood and MDF segments. MDF volumes expected to grow >20% YoY in Q4FY26 and EBITDA margins are expected to recover to ~16% from Q4FY26 onwards, as operations stabilise and utilisation improves. The company is adding a second MDF line of ~700 CBM/day, with commissioning targeted in ~18 months; while incremental growth will continue being funded through internal accruals, keeping the leverage in check. FY26 capex is expected to be Rs 4bn, though the phasing beyond FY26 remains contingent on land acquisition timelines.

**Revise estimates, maintain HOLD:** CPBI has been reporting a strong operating performance for the plywood segment, for the past 6 consecutive quarters. We have revised our FY26-28 estimates to reflect a robust volume growth in Ply/MDF/PB and also factors in CPBI's capex plans. Roll forward to Dec-27EPS and ascribe unchanged 40x 1YF multiple to arrive at TP of Rs 840 per share (Rs 800 earlier). maintain HOLD on limited upside.

## Key changes

| Target | Rating |
|---|---|
| ▲ | ◀ ▶ |

| | |
|---|---|
| Ticker/Price | CPBI IN/Rs 786 |
| Market cap | US$ 1.9bn |
| Free float | 27% |
| 3M ADV | US$ 0.9mn |
| 52wk high/low | Rs 897/Rs 650 |
| Promoter/FPI/DII | 73%/4%/18% |

Source: NSE | Price as of 5 Feb 2026

## Key financials

| Y/E 31 Mar | FY25A | FY26E | FY27E |
|---|---|---|---|
| Total revenue (Rs mn) | 45,278 | 52,694 | 59,118 |
| EBITDA (Rs mn) | 4,866 | 6,502 | 8,146 |
| Adj. net profit (Rs mn) | 1,731 | 2,702 | 3,701 |
| Adj. EPS (Rs) | 7.8 | 12.1 | 16.6 |
| Consensus EPS (Rs) | 7.8 | 13.5 | 21.0 |
| Adj. ROAE (%) | 7.6 | 10.8 | 13.3 |
| Adj. P/E (x) | 101.0 | 64.7 | 47.2 |
| EV/EBITDA (x) | 38.1 | 29.0 | 23.3 |
| Adj. EPS growth (%) | (48.3) | 56.1 | 37.0 |

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance




Source: NSE

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

**BUY**
**TP: Rs 1,013 | ⮝ 25%**

## ALEMBIC PHARMA | Pharmaceuticals | 05 February 2026

# Domestic business expected to recover from FY27

- **Sales/EBITDA/PAT were 0.5%/-5.8%/-24.6% below our estimates due to 5% higher RM cost. APAT was 1.2% below our estimates**
- **Domestic sales to pick from 1QFY27 and growth likely to report at par with the IPM with the aid of internal restructuring**
- **Lower EBITDA margin led to reduction in EPS by 17%/10%6% for FY26/27E/&28E. Reduce ascribed PE to 21 to arrive at a PT of Rs 1013**

Foram Parekh
Research Analyst
research@bobcaps.in

**Earnings below Estimates** – Sales grew by 10.8% YoY to Rs 18.7 bn, primarily driven by 35.8% YoY growth in the RoW region, 6.2% YoY growth in the India region, and 6.1% YoY growth in the US region to Rs 5.5 bn. Healthy growth from international markets (generic portfolio) resulted in a 223bps contraction in gross margin to 71.8%. Operating leverage played out during the quarter, with other expenses (excluding R&D) contributing 24% of sales in 3QFY26 versus 27% in 3QFY25, leading to a 27bps decline in EBITDA margin to 15.6%. During the quarter, there was an exceptional cost of Rs 422 mn attributed to a one-time labour code expense, resulting in a 3.9% YoY decline in PAT to Rs 1.3 bn. Adjusting for the one-time cost, PAT grew by 28% YoY to Rs 1.7 bn.

**Domestic growth likely to pick up in 1QFY27E –** India region reported growth 1% above our estimates to Rs 6.5bn. The growth was driven by 22% YoY growth in the Animal health segment and 3% YoY growth in the Specialty segment which was offset by 1% decline in the Acute segment. The company expects domestic sales to recover from 1QFY27 through internal measures; thus, we expect domestic sales to grow at a CAGR of 9%, at par with the IPM, from FY26-28E to Rs 29.6bn in FY28E.

**US sales growth to be driven by new launches –** US sales reported 4% below our estimates to Rs 5.5 bn. The growth was muted due to price erosion in the US generics. The company expects to launch its first specialty brand Pivya in 4QFY26, whose full year impact is expected in FY27E, with a scale up over 12-18 months from launch. The company continues to spend 8-9% of its sales on R&D, thus cumulatively have 23 ANDA approvals and expects to launch 4-5 products in 4QFY26. Overall, we expect US sales to grow at a CAGR of 11% from FY26-28E.

**Our View –** As Earnings were lower than estimates on operational front followed by muted 4QFY26 earnings (Q2&Q3 stronger for acute), EBITDA Margin for FY26 is expected to report ~15.8% (9MFY26 reported at 16.2%). Hence, we reduce EPS for FY26/27E/28E by 17%/10% and 6% respectively. Proportionately, we reduce, our ascribe PE to 21x (earlier 23x) and roll forward to Dec'27 EPS to arrive at a PT of Rs 1013, implying 25% upside on the stock, thus maintaining BUY on the stock.

### Key changes

| Target | Rating |
|---|---|
| ▼ | ◄ ► |

| | |
|---|---|
| Ticker/Price | ALPM IN/Rs 810 |
| Market cap | US$ 1.8bn |
| Free float | 31% |
| 3M ADV | US$ 1.3mn |
| 52wk high/low | Rs 1,108/Rs 725 |
| Promoter/FPI/DII | 70%/5%/13% |

Source: NSE | Price as of 5 Feb 2026

### Key financials

| Y/E 31 Mar | FY25A | FY26E | FY27E |
|---|---|---|---|
| Total revenue (Rs mn) | 66,721 | 73,338 | 81,438 |
| EBITDA (Rs mn) | 10,082 | 11,554 | 13,595 |
| Adj. net profit (Rs mn) | 5,697 | 6,417 | 7,963 |
| Adj. EPS (Rs) | 29.0 | 32.6 | 40.5 |
| Consensus EPS (Rs) | 29.0 | 35.9 | 45.2 |
| Adj. ROAE (%) | 11.8 | 12.3 | 14.0 |
| Adj. P/E (x) | 27.9 | 24.8 | 20.0 |
| EV/EBITDA (x) | 15.0 | 12.9 | 11.2 |
| Adj. EPS growth (%) | (7.4) | 12.5 | 24.1 |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance




Source: NSE

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

**BUY**
**TP: Rs 6,100 | ⮝ 21%**

**CERA SANITARYWARE** | Building Materials | 06 February 2026

## Q3FY26: Topline rebound, margins under pressure

- **Revenue beats estimates by ~7%, while cost inflation led to EBITDA and APAT miss by ~18% and ~25% in Q3FY26**
- **Revenue grew 10% YoY, led by 18%/6% YoY growth in Faucets/Sanitaryware, respectively**
- **Revise estimates downwards, roll forward to Dec-26 TP of Rs 6,100 (ascribe 30x Dec-27EPS), maintain BUY**

**Vineet Shanker**
**Research Analyst**
research@bobcaps.in

**Mixed Q3:** CRS reported a revenue beat of ~7% in Q3FY26, with consolidated revenue rising 10.3% YoY/18.2% QoQ, driven by a sharp sequential recovery. But, profitability missed expectations, with EBITDA 17.6% below our estimate as margins contracted by 337 bps YoY to 10.2% meaningfully during the quarter. Consequently, APAT declined 18.7% YoY and missed our estimate by 25.1%.

**Highlights:** Sanitaryware revenue was up 6% YoY, while Faucetware reported a robust 18% YoY growth. Gross margin contracted significantly by 320bps YoY to 50.1%, on account of a sharp brass-cost hike. On a 9MFY26 basis, revenue growth stood at a muted 4.7% YoY led by sanitaryware/faucet growth of 2.6%/8.3% YoY. EBITDA and APAT declined 9.6% YoY and 12.7% YoY.

**Guidance:** CRS expects growth trajectory to remain sustainable in the near term, with Q4 maintaining the momentum for double-digit growth, leading to 7-8% full-year growth. For Senator and Polyplus, combined sales are revised to ~Rs 200 mn for the current year (from the earlier Rs 400-450mn projection) due to delays in store readiness, with next-year projections for Senator at Rs 1-1.24bn. Overall, the company anticipates returning to 13-14% EBITDA margins in Q4FY26.

**Revise estimates; maintain BUY:** CRS EBITDA is projected to grow at a moderate pace of 6.1% CAGR over FY25-FY28E. However, we maintain BUY as (a) CRS's initiative to enter the Economy-range bath fittings segment and enhance revenue contribution from its luxury portfolio will expand the addressable market opportunity and be margin accretive b) likely to generate healthy ROE (~15% over FY26-FY28) c) reasonable valuations (the stock trades at a P/E of 29.6x on 1YF basis vs 5Y average of 35.1x). We have cut our EPS estimates (-7.6%/-10.7%/-4.2% for FY26E/FY27E/FY28E), based on weak Q3 result and factor gradual recovery in growth and profitability. Rolling forward to Dec-27EPS and ascribing 30x (vs 35x) to factor in lower profitability, on account of input cost inflation as it moderates EBITDA growth, we arrive at Dec-26 TP of Rs 6,100. Maintain BUY

### Key changes

| Target | Rating |
|---|---|
| ▼ | ◀ ▶ |

| | |
|---|---|
| Ticker/Price | CRS IN/Rs 5,054 |
| Market cap | US$ 721.5mn |
| Free float | 46% |
| 3M ADV | US$ 1.2mn |
| 52wk high/low | Rs 7,275/Rs 4,797 |
| Promoter/FPI/DII | 54%/16%/14% |

Source: NSE | Price as of 5 Feb 2026

### Key financials

| Y/E 31 Mar | FY25A | FY26E | FY27E |
|---|---|---|---|
| Total revenue (Rs mn) | 19,262 | 19,981 | 21,621 |
| EBITDA (Rs mn) | 3,041 | 2,570 | 2,995 |
| Adj. net profit (Rs mn) | 2,511 | 2,059 | 2,273 |
| Adj. EPS (Rs) | 194.7 | 159.6 | 176.3 |
| Consensus EPS (Rs) | 194.7 | 187.7 | 214.8 |
| Adj. ROAE (%) | 18.4 | 14.3 | 14.4 |
| Adj. P/E (x) | 26.0 | 31.7 | 28.7 |
| EV/EBITDA (x) | 19.0 | 22.5 | 19.0 |
| Adj. EPS growth (%) | 5.3 | (18.0) | 10.4 |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance




Source: NSE

**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.**

# Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
SEBI Research Analyst Registration No: **INH000000040 valid till 01 February 2030**
Brand Name: **BOBCAPS**
Trade Name: **www.barodaetrade.com**
CIN: **U65999MH1996GOI098009**

Logo:

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

**Recommendation scale: Recommendations and Absolute returns (%) over 12 months**

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

**Analyst certification**

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

**Important disclosures**

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

**General disclaimers**

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

**Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

**Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

**Distribution into the United Kingdom ("UK"):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as **"MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

**No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

**Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.